Isotype Control Antibody Market size was valued at USD 85.7 billion in 2024 and is anticipated to surpass USD 383.4 billion by 2037, registering a CAGR of 13.3% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of isotype control antibody is assessed at USD 97.1 billion.
The isotype control antibody market is gaining traction owing to improved immunology techniques. This has raised the demand for controls with high reliability within antibody-based assays such as flow cytometry and immunohistochemistry. For instance, in March 2024, Evaxion Biotech A/S organized a research & development program that highlighted its core AI-Immunology platform for finding, designing, and developing target vaccines. Isotype control antibodies are a crucial benchmark to validate experimental results for specificity, thereby improving the accuracy of data interpretation. For instance, in November 2024, Innate Pharma SA reported preclinical results showing the potential of IPH6501, a proprietary NK cell engager that targets CD20 from the ANKET platform and includes an IL-2v.
With the trend toward personalized medicine, the need for biomarker discovery and therapeutic monitoring further increases the demand for high-quality isotype controls. In addition, research funding options are being made available to address the diverse needs of experimental applications. For instance, in October 2024, Johnson & Johnson revealed that it will invest over USD 2 billion to construct a cutting-edge biologics manufacturing plant in Wilson. This expansion aimed at advancing more than 70 novel therapeutics to increase the company's portfolio and pipeline of cutting-edge biologics. Moreover, the growth in the biotechnology industry is fueling the demand. For instance, according to IBEF, it is expected that by 2025, the Indian biotechnology industry will reach USD 150 billion and could easily reach USD 270-300 billion by the year 2030.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
13.3% |
|
Base Year Market Size (2024) |
USD 85.7 billion |
|
Forecast Year Market Size (2037) |
USD 383.4 billion |
|
Regional Scope |
|
End user (Hospitals, Research Institutes, Long-term Care Facilities)
The hospital segment is set to dominate over 45.2% isotype control antibody market share by 2037, primarily due to the critical role they play in conducting advanced diagnostic and therapeutic procedures. This involves hospitals utilizing isotype control antibodies in their various applications to serve the patient well through funding and expansions. For instance, in May 2024, LabGenius closed a series B funding round at USD 42.6 million to lead its way in using machine learning to find new therapeutic antibodies. With this investment, LabGenius has raised a total of USD 70.7 million. With the rise in high technology in hospitals and the expansion of their research facilities, tremendous demand for isotype control antibodies will emerge from this segment.
Disease Indication (CNS Disorders, Cardiovascular Diseases, Cancer, Auto-immune Disorders)
The cancer segment is anticipated to dominate the isotype control antibody market by 2037 attributable primarily due to the rapidly growing incidence of various cancers. For instance, in May 2024, according to data from the National Cancer Institute, globally, there were 9.7 million cancer-related deaths and nearly 20 million new cases in 2022. It is anticipated that there will be 15.3 million cancer-related deaths and 29.9 million new cancer cases annually by 2040. Consequently, this has in turn generated demand for precise diagnostic and therapeutic tools. It follows the advancement of research in oncology that there has been a continuous demand for precise identification and validation of biomarkers in cancer studies.
Our in-depth analysis of the global isotype control antibody market includes the following segments:
|
End user |
|
|
Disease Indication |
|
North America Market Statistics
North America in isotype control antibody market is set to capture over 45.9% revenue share by 2037, due to the rising development costs and the need for rapid market access. This, further fuels interest in outsourcing biopharmaceutical operations which will streamline operations and help in advancing therapeutic innovations. Moreover, due to the growing number of applications for antibody drug discovery platforms and services, investors are showing a great deal of interest in the sector in the region.
The U.S. Isotype control antibody market is likely to unfold remarkable growth opportunities during the projected timeline i.e. 2025-2037. To increase the range of services offered and gain expertise in the discovery of antibodies, several businesses are merging and acquiring one another. For instance, in March 2023, Twist Bioscience Corporation revealed an integrated suite of antibody discovery services that clients can use. The product combines an in vivo immunization strategy acquired through the acquisition of Abveris in November 2021 for USD 190 million.
The isotype control antibody market in Canada is witnessing significant growth due to its strategy to expand and accelerate the therapeutic drugs developments. For instance, in June 2021, AbCellera announced that it is set to build the first-ever Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies in Vancouver. In addition, the 130,000-square-foot facility would increase AbCellera's capacity to offer its partners a comprehensive solution for accelerating their programs from a drug target to the submission of an Investigational New Drug (IND) application.
Asia Pacific Market Analysis
The Isotype control antibody market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline i.e. 2025-2037. The region is home to a thriving biopharmaceutical industry described by wide, creative drug development and research. The region’s biotechnology framework, joined with a huge interest in biomedical examination, drives the interest in isotype control antibodies as essential assets for the exploration and revelation of medications.
The Isotype control antibody market in India is expecting substantial growth owing to the rising need for more specialized and superior healthcare facilities and the development of state-of-the-art healthcare infrastructure. For instance, in January 2024, according to the International Trade Administration, in 2022, the Indian healthcare sector generated over USD 370 billion. In addition, Nexdigm predicts that by 2026, the healthcare sector will grow to a value of over USD 610 billion.
The Isotype control antibody market in China is gaining traction due to heavy investments by pharmaceutical players in cell therapy and antibody product breakthroughs. For instance, in January 2023, IASO Biotherapeutics announced that it had completed nearly USD 75 million in series C1 funding. With the new funding, the company aimed to continue working toward its goal of bringing hope to patients in China requiring effective cell therapies and antibody products. Furthermore, it will elevate its reach throughout the country by accelerating the development and commercialization of innovative drugs.
The isotype control antibody market is revolutionizing due to the collaborative endeavors of companies in leveraging their expertise in R&D to create novel therapies. For instance, in May 2024, AbTherx and Jackson Laboratory announced a strategic partnership to create and market innovative tools to speed up antibody discovery and reduce the risk of developing critical new treatments. This partnership will involve co-development activities and make use of AbTherx's AtlasTM Mouse platform and JAX's vast model research experience to tackle important issues that affect drug developers of all sizes.
Here's the list of some key players:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?